Transcode Therapeutics Inc Stock Price, News & Analysis

TransCode Therapeutics (NASDAQ: RNAZ) reported positive progress in its Phase 1a clinical trial of TTX-MC138, a first-in-class therapeutic targeting miR-10b for metastatic cancer treatment. Key findings include:

- 13 patients received treatment across 4 dose levels (0.8 mg/kg to 4.8 mg/kg)
- No significant safety or dose-limiting toxicities reported
- Two patients maintained stable disease for ~7 months
- 8 patients continue treatment in 28-day cycles
- PK/PD analysis shows promising results with miR-10b target engagement in 5 out of 6 analyzed patients

The positive tolerability profile and PK/PD results support advancement to the Phase 1b expansion portion of the trial.

TransCode Therapeutics (RNAZ) announced the adjournment of its Special Meeting scheduled for April 21, 2025, due to insufficient quorum, with only 12.73% of eligible shares represented. The meeting will reconvene as a virtual Adjourned Special Meeting on May 2, 2025.

The meeting aims to vote on two key proposals: Proposal One seeks approval for a reverse stock split ranging from 1:10 to 1:40 ratio, while Proposal Two addresses the potential need for further meeting adjournments. Stockholders of record as of April 2, 2025, can vote through multiple methods including mail, internet, telephone, or during the virtual meeting at www.virtualshareholdermeeting.com/RNAZ2025SM2.

TransCode Therapeutics (NASDAQ: RNAZ) has announced significant progress in its Phase 1 clinical trial of TTX-MC138, their lead therapeutic candidate designed to inhibit microRNA-10b in metastatic cancer. The first patient in Cohort 4 has received initial dosing, with two additional patients scheduled for treatment.

Key highlights include:

• Ten patients treated across four cohorts at escalating dose levels
• No significant safety or dose-limiting toxicities reported
• Seven patients remain on study for continued treatment
• Cohort 4 dosing is approximately 50% higher than Cohort 3
• Ongoing data analysis from Cohorts 1-3 shows pharmacokinetic and pharmacodynamic profiles consistent with preclinical results and Phase 0 trial

The Safety Review Committee has approved additional patient enrollment in Cohort 3 to further establish the safety profile of TTX-MC138.

TransCode Therapeutics (RNAZ) has completed a registered direct offering, raising $10 million in gross proceeds through the sale of 10,250,000 shares of common stock and accompanying warrants. The offering was priced at $0.98 per share at-the-market under Nasdaq rules, with each share accompanied by warrants to purchase additional shares.

The RNA oncology company plans to utilize the proceeds primarily for product development activities, including clinical trials of their lead therapeutic candidate TTX-MC138, IND-enabling studies, working capital, and general corporate purposes. ThinkEquity served as the sole placement agent for this offering, which was conducted under an effective shelf registration statement filed with the SEC.

TransCode Therapeutics (NASDAQ: RNAZ) has announced a registered direct offering of 10,250,000 shares of common stock and warrants at $0.98 per share. The offering includes warrants to purchase up to 10,250,000 additional shares at an exercise price of $0.86, exercisable for five years upon issuance.

The offering, expected to close on March 25, 2025, aims to raise approximately $10 million in gross proceeds. The funds will support product development activities, including clinical trials for TTX-MC138 (their lead therapeutic candidate), IND-enabling studies, working capital, and general corporate purposes. ThinkEquity serves as the exclusive placement agent for this at-the-market offering under Nasdaq rules.

TransCode Therapeutics (NASDAQ: RNAZ) has received approval from the Safety Review Committee (SRC) to proceed with Cohort 4 in its Phase I/II clinical trial for TTX-MC138, a first-in-class RNA therapeutic for metastatic cancers. The approval follows favorable safety data from Cohort 3, with no significant safety issues or dose-limiting toxicities reported across all three previous cohorts.

Key highlights:

• 6 out of 9 treated patients remain on study, with one patient receiving 7 doses over approximately 7 months
• Cohort 4 will receive a dose approximately 50% higher than Cohort 3
• SRC approved additional patient enrollment in Cohort 3
• Pharmacokinetic and pharmacodynamic data from Cohorts 1 and 2 align with preclinical and Phase 0 trial results
• Preliminary analysis suggests dose levels of 0.8-1.6 mg/kg could represent an efficacious range

TransCode Therapeutics (RNAZ), the RNA Oncology Company, announced the results of its Special Meeting held on February 25, 2025, following adjournment from February 4, 2025. Shareholders achieved a quorum and approved two key proposals:

• Proposal One: Approved the issuance of Common Stock upon exercise of Series C and D Warrants, including adjustments to warrant exercise prices, an alternative cashless exercise feature for Series D Warrants, and potential future price adjustments (subject to a $2.4882 floor price)
• Proposal Two: Approved the ability to adjourn the Special Meeting if needed for further proxy solicitation regarding the Issuance Proposal

TransCode Therapeutics (NASDAQ: RNAZ) has announced the completion of initial dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, its lead candidate. Three patients were enrolled and dosed in Cohort 3, with the dose being approximately double that of Cohort 2. The Safety Review Committee approved the third cohort after reviewing safety and pharmacokinetic (PK) data from Cohorts 1 and 2.

Notable findings include: no significant safety or dose limiting toxicities reported across all nine trial patients; several patients from Cohorts 1 and 2 continuing treatment in 28-day cycles; and PK/PD analyses showing consistency with preclinical and Phase 0 trial results. Cohort 1 demonstrated 66% inhibition of miR-10b at 24 hours post-infusion, matching Phase 0 observations. TTX-MC138 showed increased activity with dose escalation in Cohort 2, maintaining consistency across subsequent administrations.

TransCode Therapeutics (RNAZ) announced the adjournment of its Special Meeting scheduled for February 4, 2025, due to insufficient quorum. Only 29.94% of eligible voting shares were represented, falling short of the required one-third minimum. The meeting has been rescheduled to February 25, 2025, at 9:30 a.m. Eastern time.

The adjourned meeting will address two key proposals: Proposal One concerns the issuance of Common Stock upon exercise of Series C and D Warrants, including price adjustments and exercise features, subject to a floor price of $2.4882. Proposal Two addresses the potential need for further meeting adjournments if insufficient votes are received for Proposal One.

Stockholders of record as of December 17, 2024, can vote through multiple methods including mail, internet, telephone, or during the virtual meeting. All votes must be received by 11:59 p.m. Eastern time on February 24, 2025.